Revolution Medicines (RVMD) Accumulated Depreciation (2019 - 2026)

Revolution Medicines' Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• On a quarterly basis, Accumulated Depreciation rose 31.22% year-over-year to $30.7 million in Q1 2026; TTM through Mar 2026 was $30.7 million, a 31.22% increase from a year earlier, with the FY2025 full-year figure at $28.5 million, up 30.66% from the prior year.
• Accumulated Depreciation climbed to $30.7 million in Q1 2026 per RVMD's latest filing, from $28.5 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $30.7 million in Q1 2026 and bottomed at $11.6 million in Q1 2022.
• The 5-year median for Accumulated Depreciation is $18.9 million (2024), against an average of $19.9 million.
• Across the five-year window, Accumulated Depreciation soared 35.59% in 2023 and climbed 19.86% in 2024, its largest moves.
• Year by year, Accumulated Depreciation stood at $14.5 million in 2022, then gained by 22.12% to $17.7 million in 2023, then advanced by 23.34% to $21.8 million in 2024, then soared by 30.66% to $28.5 million in 2025, then advanced by 7.6% to $30.7 million in 2026.
• Per Business Quant, the three latest RVMD Accumulated Depreciation figures stand at $30.7 million (Q1 2026), $28.5 million (Q4 2025), and $27.0 million (Q3 2025).